Mebendazole kills Ovarian Cancer Cells that are resistant to Chemotherapy
2021 paper by Huang - Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways.
Ovarian cancer is the third most common cancer and the second most common cause of gynecologic cancer death in women. Due to the lack of effective early detection strategies, over 80% of ovarian cancers are usually diagnosed with metastatic lesions.
Although studies are limited, researchers have found mebendazole to have anti-cancer properties like fenbendazole. It stops worms from absorbing glucose, which they need to grow. Researchers have found that it can also prevent cancer cells from absorbing glucose, keeping them from expanding.
While most of the pre-clinical research uses mebendazole, probably because it is the FDA-approved-for-humans form of fenbendazole, virtually most of the self-treating clinical reports involve the use of fenbendazole.
Read More: Fenbendazole vs Mebendazole for Cancer
Ovarian cancer is the third most common cancer and the second most common cause of gynecologic cancer death in women. Due to the lack of effective early detection strategies, over 80% of ovarian cancers are usually diagnosed with metastatic lesions.
While the first-line systemic therapy requires the combined use of platinum-based agents and paclitaxel, many ovarian cancer patients have recurrence and eventually succumb to chemo-resistance.
The antiparasitic drug mebendazole (MBZ) is one of the most promising drugs with repurposing potential Mebendazole was able to inhibit and kill Ovarian cancer cells that were resistant to cisplatin chemotherapy.
Fenbendazole vs. Mebendazole
Fenbendazole and mebendazole are similar in that they both eliminate parasitic worms, but there is a difference. Mebendazole is approved for human consumption by the FDA, while fenbendazole is only approved for veterinary use and has not been approved for human use.
Mebendazole is the form that is approved for human use while fenbendazole is approved for veterinary use. The main difference is the cost. Mebendazole is expensive ~$450 per pill (two pills of mebendazole cost just $4 in the UK.), while fenbendazole is inexpensive ~48 cents per 222 mg free powder dose (Williams, 2019). Albendazole is the form used to treat intestinal parasites in India and these cost 2 cents per pill.
While most of the pre-clinical research uses mebendazole, probably because it is the FDA-approved-for-humans form of fenbendazole, virtually most of the self-treating clinical reports involve the use of fenbendazole.
While fenbendazole for human cancer has gained more popularity with some interesting fenbendazole cancer success stories, some research suggests mebendazole might be more effective for treating different types of tumors. For example, research studies have shown that mebendazole could be more effective for brain, prostate, and ovarian cancers.
Clinical Trials
There are more than 10 studies for mebendazole for cancer in ClinicalTrials.gov but only one for fenbendazole for cancer.
Comments
Post a Comment